Paratek pub­lish­es pos­i­tive PhI­II da­ta on ap­proved Nuzyra; Al­ler­gan set­tles opi­oid law­suits in two Ohio coun­ties

Paratek Phar­ma­ceu­ti­cals $PRTK Nuzyra (omada­cy­cline) has met all pri­ma­ry and sec­ondary clin­i­cal study end­points in their OA­SIS-2 Phase III clin­i­cal tri­al, ac­cord­ing to re­sults pub­lished in The Lancet In­fec­tious Dis­eases. In the study, in­volv­ing 735 adults with AB­SS­SI, Nuzyra was shown to be as ef­fec­tive as Pfiz­er‘s $PFE twice-dai­ly oral-on­ly Zyvox (line­zol­id). Nuzyra is cur­rent­ly avail­able in the US as a once-dai­ly oral and in­tra­venous an­tibi­ot­ic for the treat­ment of adults with com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia and AB­SS­SI. The drug is al­so be­ing stud­ied for the treat­ment of uri­nary tract in­fec­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.